ArticleBMC cardiovascular disorders2026
Apoptotic markers and Dectin-1
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTo investigate the prognostic value of apoptotic markers and dendritic cell-associated C-type lectin-1 (Dectin-1)-positive cells on cardiac function in patients with ST-elevation myocardial infarction (STEMI) after percutaneous coronary intervention (PCI).
methodsPatients with STEMI who underwent successful PCI at Wuhan Hospital of Traditional Chinese Medicine from March 2019 to June 2022 were retrospectively analyzed. Patients were divided into two groups based on whether left ventricular ejection fraction (LVEF) improved < 10% (the LVEF non-improvement group) or ≥ 10% (the LVEF improvement group) at 30 days post-PCI compared to that at 24 h after PCI. Blood test results, imaging measurements, apoptotic markers, and soluble Dectin-1 level were compared between the two groups. Multivariable logistic regression was performed adjusting for age, sex, diabetes, and LAD occlusion rate.
resultsAmong 96 patients included, 28 showed LVEF improvement. Compared to that in the LVEF non-improvement group, the expression levels of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and Dectin-1 were significantly lower in the LVEF improvement group (P < 0.05), while the expression level of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was significantly higher in the LVEF improvement group (P < 0.05). TRAIL (P = 0.047) and TWEAK (P = 0.005) were independently associated with LVEF improvement after adjusting for confounders. TRAIL, TWEAK, soluble Dectin-1, and a combination of these three biomarkers exhibited prediction sensitivity for LVEF improvement in post-PCI patients with STEMI of 50.00%, 60.71%, 67.86%, 78.57%, respectively, and specificity of 79.41%, 73.53%, 57.35%, 82.35%, respectively.
conclusionsApoptotic markers and soluble Dectin-1 may serve as potential predictors of cardiac function recovery in patients with STEMI following PCI, and the combination of these markers showed improved prognostic value, though further validation in larger, prospective cohorts is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.